Antitumor Metallodrugs that Target Proteins

Area of Science:

• Medicinal Chemistry
• Biochemistry
• Oncology

Background:

• Platinum-based chemotherapy is a cornerstone for treating various cancers by inducing apoptosis via DNA targeting.
• However, off-target reactivity with other biomolecules leads to significant side effects in patients.
• Developing metal compounds that selectively target proteins presents a promising strategy to mitigate these drawbacks.

Purpose of the Study:

• To review novel metal complexes with protein-targeting mechanisms for cancer therapy.
• To highlight compounds demonstrating potential for improved tumor accumulation, selectivity, and antiproliferative efficacy.
• To emphasize the role of bioanalytical methods in validating new therapeutic targets and pathways.

Main Methods:

• Review of original research and development in anticancer metal compounds.
• Analysis of compounds exhibiting selective protein interactions.
• Identification of lead structures progressing towards clinical application.

Main Results:

• Several novel metal complexes show anticancer activity through protein interactions, distinct from DNA-targeting agents.
• These compounds demonstrate potential for enhanced tumor targeting and reduced systemic toxicity.
• Selected compounds are advancing through preclinical and clinical development stages.

Conclusions:

• Metal complexes targeting proteins represent a promising alternative to traditional platinum-based chemotherapy.
• Selective protein interaction may lead to improved therapeutic outcomes and reduced patient side effects.
• Continued development and bioanalytical validation are crucial for translating these novel agents into clinical practice.